Unknown

Dataset Information

0

Liposome Formulations for the Strategic Delivery of PARP1 Inhibitors: Development and Optimization.


ABSTRACT: The development of a lipid nano-delivery system was attempted for three specific poly (ADP-ribose) polymerase 1 (PARP1) inhibitors: Veliparib, Rucaparib, and Niraparib. Simple lipid and dual lipid formulations with 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1'-glycerol) sodium salt (DPPG) and 1,2-dipalmitoyl-sn-glycero-3-phosphocoline (DPPC) were developed and tested following the thin-film method. DPPG-encapsulating inhibitors presented the best fit in terms of encapsulation efficiency (>40%, translates into concentrations as high as 100 µM), zeta potential values (below -30 mV), and population distribution (single population profile). The particle size of the main population of interest was ~130 nm in diameter. Kinetic release studies showed that DPPG-encapsulating PARP1 inhibitors present slower drug release rates than liposome control samples, and complex drug release mechanisms were identified. DPPG + Veliparib/Niraparib presented a combination of diffusion-controlled and non-Fickian diffusion, while anomalous and super case II transport was verified for DPPG + Rucaparib. Spectroscopic analysis revealed that PARP1 inhibitors interact with the DPPG lipid membrane, promoting membrane water displacement from hydration centers. A preferential membrane interaction with lipid carbonyl groups was observed through hydrogen bonding, where the inhibitors' protonated amine groups may be the major players in the PARP1 inhibitor encapsulation mode.

SUBMITTER: Conceicao CJF 

PROVIDER: S-EPMC10223686 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Liposome Formulations for the Strategic Delivery of PARP1 Inhibitors: Development and Optimization.

Conceição Carlota J F CJF   Moe Elin E   Ribeiro Paulo A PA   Raposo Maria M  

Nanomaterials (Basel, Switzerland) 20230511 10


The development of a lipid nano-delivery system was attempted for three specific poly (ADP-ribose) polymerase 1 (PARP1) inhibitors: Veliparib, Rucaparib, and Niraparib. Simple lipid and dual lipid formulations with 1,2-dipalmitoyl-sn-glycero-3-phospho-rac-(1'-glycerol) sodium salt (DPPG) and 1,2-dipalmitoyl-sn-glycero-3-phosphocoline (DPPC) were developed and tested following the thin-film method. DPPG-encapsulating inhibitors presented the best fit in terms of encapsulation efficiency (>40%, tr  ...[more]

Similar Datasets

| S-EPMC6384625 | biostudies-literature
| S-EPMC4982460 | biostudies-literature
| S-EPMC10954414 | biostudies-literature
| S-EPMC4027536 | biostudies-other
| S-EPMC8043385 | biostudies-literature
| S-EPMC5666793 | biostudies-literature
| S-EPMC8512385 | biostudies-literature
| S-EPMC3461335 | biostudies-literature
2017-06-12 | GSE77175 | GEO
| S-EPMC10232664 | biostudies-literature